US Stock MarketDetailed Quotes
IMVT Immunovant
- 30.470
- +1.120+3.82%
Close Apr 15 16:00 ET
- 30.710
- +0.240+0.79%
Post 18:57 ET
4.43BMarket Cap-16834P/E (TTM)
30.610High29.280Low1.20MVolume29.510Open29.350Pre Close36.16MTurnover1.86%Turnover RatioLossP/E (Static)145.29MShares45.58052wk High6.52P/B1.96BFloat Cap15.39052wk Low--Dividend TTM64.36MShs Float53.750Historical High--Div YieldTTM4.53%Amplitude3.145Historical Low30.135Avg Price1Lot Size
Immunovant Key Stats
Quarterly+Annual
YOY
| (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | (FY)Mar 31, 2022 | (Q4)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -1.52%-47.1M | -197.53%-60.06M | 28.03%-47.37M | -77.35%-188.19M | -69.30%-55.79M | -45.46%-46.4M | -0.69%-20.19M | -210.26%-65.82M | -27.34%-106.11M | -46.50%-32.96M |
| Net income from continuing operations | 18.68%-51.42M | -22.40%-58.66M | -83.13%-73.94M | -34.60%-210.96M | -25.99%-59.43M | -52.78%-63.23M | -27.12%-47.93M | -32.50%-40.37M | -45.89%-156.73M | -67.52%-47.17M |
| Depreciation and amortization | 18.37%58K | 21.74%56K | 20.45%53K | 53.17%193K | 38.46%54K | 48.48%49K | 64.29%46K | 69.23%44K | 93.85%126K | 77.27%39K |
| Other non cash items | 3.87%295K | 4.27%293K | 3.94%290K | 2.26%1.13M | 4.36%287K | 161.74%284K | -37.00%281K | -66.98%279K | 69.89%1.11M | 150.37%275K |
| Change In working capital | -182.35%-6.25M | -163.74%-12.28M | 146.44%15.54M | -171.67%-10.85M | -308.44%-4.25M | 3,237.60%7.59M | 118.32%19.26M | -839.36%-33.46M | 231.63%15.14M | 191.98%2.04M |
| -Change in receivables | -90.97%266K | -105.75%-561K | 85.01%-142K | 204.33%12.23M | 112.18%463K | 139.11%2.95M | 5,616.38%9.76M | -350.95%-947K | -957.58%-11.72M | ---3.8M |
| -Change in prepaid assets | 167.99%2.84M | -10.49%-1.02M | 189.79%8.26M | -1,060.83%-20.53M | -216.23%-6.24M | -1,294.98%-4.17M | -179.81%-925K | -383.19%-9.2M | 183.80%2.14M | -561.74%-1.97M |
| -Change in payables and accrued expense | -199.34%-9.05M | -197.06%-10.39M | 133.51%7.72M | -105.40%-1.4M | -78.19%1.82M | 15.82%9.11M | 36.14%10.7M | -1,347.40%-23.03M | 352.91%25.9M | 276.12%8.33M |
| -Change in other current liabilities | -6.94%-308K | -7.39%-305K | -7.12%-301K | 2.88%-1.15M | 43.95%-292K | -4.73%-288K | -1,134.78%-284K | 21.94%-281K | -47.74%-1.18M | -369.37%-521K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -1.52%-47.1M | -197.53%-60.06M | 28.03%-47.37M | -77.35%-188.19M | -69.30%-55.79M | -45.46%-46.4M | -0.69%-20.19M | -210.26%-65.82M | -27.34%-106.11M | -46.50%-32.96M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -33.67%-131K | -9.68%-34K | -7.14%-45K | 22.44%-197K | 77.97%-26K | -32.43%-98K | 29.55%-31K | -133.33%-42K | -20.95%-254K | -24.21%-118K |
| Net PPE purchase and sale | -33.67%-131K | -9.68%-34K | -7.14%-45K | 22.44%-197K | 77.97%-26K | -32.43%-98K | 29.55%-31K | -133.33%-42K | -20.95%-254K | -24.21%-118K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -33.67%-131K | -9.68%-34K | -7.14%-45K | 22.44%-197K | 77.97%-26K | -32.43%-98K | 29.55%-31K | -133.33%-42K | -20.95%-254K | -24.21%-118K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 565.21%469.84M | 148K | 4,138.10%890K | -64.58%70.89M | 233K | 70.63M | 0 | -76.92%21K | -47.76%200.13M | 0 |
| Net common stock issuance | ---- | ---- | ---- | --70.5M | --0 | ---- | ---- | ---- | --0 | --0 |
| Proceeds from stock option exercised by employees | 671.96%3.11M | --148K | 4,138.10%890K | --657K | --233K | --403K | --0 | --21K | --0 | --0 |
| Net other financing activities | ---- | ---- | ---- | -100.14%-272K | --0 | ---- | ---- | ---- | 143,049.29%200.13M | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 565.21%469.84M | --148K | 4,138.10%890K | -64.58%70.89M | --233K | --70.63M | --0 | -76.92%21K | -47.76%200.13M | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -33.48%269.93M | -22.76%329.96M | -23.75%376.53M | 23.41%493.82M | -17.91%432.61M | -27.40%405.77M | 12.72%427.21M | 23.41%493.82M | 297.87%400.15M | 24.89%527M |
| Current changes in cash | 1,650.83%422.62M | -196.51%-59.95M | 29.34%-46.53M | -225.32%-117.51M | -68.07%-55.59M | 175.50%24.14M | -111.23%-20.22M | -211.43%-65.84M | -68.70%93.76M | -51.52%-33.07M |
| Effect of exchange rate changes | -159.55%-1.61M | 92.92%-86K | 93.91%-47K | 339.13%220K | -337.50%-490K | 13,385.00%2.7M | ---1.22M | ---772K | ---92K | ---112K |
| End cash Position | 59.71%690.94M | -33.48%269.93M | -22.76%329.96M | -23.75%376.53M | -23.75%376.53M | -17.91%432.61M | -27.40%405.77M | 12.72%427.21M | 23.41%493.82M | 23.41%493.82M |
| Free cash flow | -1.58%-47.23M | -197.24%-60.09M | 28.01%-47.42M | -77.11%-188.39M | -68.77%-55.82M | -45.43%-46.49M | -0.63%-20.22M | -210.20%-65.86M | -27.33%-106.37M | -46.40%-33.07M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg